5月28日，药明生物盘中下跌3.15%，报32.64港元，成交额8594.5万港元。此前公司于5月24日宣布拟斥资不超过4亿美元回购股份，5月26日盘中一度冲高近7%，但提振效应迅速消退。
消息面上，恒生港股通创新药指数将于6月30日剔除所有CXO企业，药明生物原占指数权重约9.8%，剔除后跟踪该指数的ETF将被动减持，加剧短期抛压。此外，大股东Biologics Holdings于5月15日以每股38.52港元减持1.5亿股套现约57.78亿港元，持股降至8.49%，仅11天后公司即宣布回购，大股东高位减持与公司低位接盘的矛盾信号令市场情绪承压。同期行业内药明康德跌3.05%、药明合联跌3.32%，CXO板块整体走弱。
药明生物是一家主要从事向生物制剂行业客户提供生物发现、开发及生产端到端解决方案及服务的投资控股公司，业务涵盖生物药及抗体偶联药物CRDMO服务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.